# DESCRIPTION

## FIELD OF THE DISCLOSURE

- define bispecific antigen binding molecules

## BACKGROUND

- motivate complement system for therapeutics

## BRIEF SUMMARY OF THE DISCLOSURE

- introduce bispecific antigen-binding molecules
- describe target antigen and complement component
- specify target antigen as bacterial, viral, or cancer cell surface antigen
- describe bispecific antigen-binding molecules binding to Staphylococcus species target antigens
- describe bispecific antigen-binding molecules binding to Pseudomonas species target antigens
- describe bispecific antigen-binding molecules binding to Influenza target antigens
- describe bispecific antigen-binding molecules binding to cancer cell surface antigens
- describe bispecific antigen-binding molecules binding to T cell surface antigens
- describe structure and function of bispecific antigen-binding molecules
- define antigen-binding domains
- describe C1q binding domains
- describe IsdB binding domains
- describe other antigen binding domains
- provide bispecific molecule embodiments
- introduce bispecific antibodies
- describe anti-Ps1 x anti-C1q bispecific antibodies
- describe anti-CD20 x anti-C1q bispecific antibodies
- describe anti-HA x anti-C1q bispecific antibodies
- describe anti-GITR x anti-C1q bispecific antibodies
- describe isolated bispecific antigen binding molecules
- describe nucleic acid molecules encoding HCVR, LCVR or CDR sequences
- describe recombinant expression vectors and host cells
- describe pharmaceutical compositions and methods of treatment
- describe therapeutic methods for inhibiting bacterial growth and treating cancer

## DETAILED DESCRIPTION

- define terminology and scope

### I. Definitions

- define bispecific antigen-binding molecules
- define antigen-binding domains
- define anti-complement component antibody
- define antigen-binding molecule
- define target antigen
- define specific target antigens
- define antibody terms
- describe antibody structure
- explain antigen-binding domains
- discuss methods for determining binding
- describe antigen-binding fragments
- explain multispecific antibodies
- discuss CDC and ADCC
- define human antibodies
- describe recombinant human antibodies
- explain hinge heterogeneity
- discuss isolated antibodies

### II. Complement Component Binding Molecules

- introduce anti-C1q antibodies
- describe C1q structure and function
- provide exemplary anti-C1q antibody sequences
- describe antibody binding properties
- provide nucleic acid molecules encoding anti-C1q antibodies
- describe methods for identifying CDRs
- provide recombinant expression vectors for anti-C1q antibody production
- describe modified glycosylation patterns for anti-C1q antibodies

### III. Target Antigen Binding Molecules

- introduce target antigen binding molecules
- describe Staphylococcus target antigens
- specify anti-IsdB antibodies
- provide antibody sequences and structures
- describe nucleic acid molecules encoding antibodies
- provide recombinant expression vectors and host cells
- define target antigen binding molecules
- provide nucleic acid molecules encoding HCVR and LCVR
- describe antibodies or antigen-binding fragments thereof
- provide nucleic acid molecules encoding anti-IsdA antibodies
- describe recombinant expression vectors and host cells
- provide nucleic acid molecules encoding various CDR sequences
- define target antigen binding molecules
- provide nucleic acid molecules encoding HCVR and LCVR
- describe antibodies or antigen-binding fragments thereof that bind Protein A
- provide nucleic acid molecules encoding anti-Protein A antibodies or portions thereof
- describe exemplary anti-Protein A antibodies
- provide nucleic acid molecules encoding various CDR sequences
- define target antigen binding molecules
- describe nucleic acid molecules encoding HCVR and LCVR
- describe antibodies or antigen-binding fragments that bind PNAG
- describe antibodies or antigen-binding fragments that bind C1fA
- describe nucleic acid molecules encoding anti-PNAG and anti-C1fA antibodies
- describe recombinant expression vectors and host cells
- describe antibodies that bind Pseudomonas species target antigen
- define target antigen binding molecules
- describe Ps1 antibodies
- describe nucleic acid molecules encoding Ps1 antibodies
- describe virus target antigens
- describe Influenza HA antibodies
- describe nucleic acid molecules encoding Influenza HA antibodies
- describe bispecific antigen-binding molecules
- define antigen binding molecules
- describe nucleic acid molecules encoding antibodies
- provide recombinant expression vectors and host cells
- introduce cancer cell target antigens
- describe anti-CD20 antibodies and antigen-binding fragments
- provide antibodies with specific CDR sequences
- define CD20 binding molecules
- provide nucleic acid molecules encoding CD20 antibodies
- describe recombinant expression vectors and host cells
- introduce immune cell target antigens
- define GITR binding molecules
- provide nucleic acid molecules encoding GITR antibodies
- provide antibodies
- describe antigen-binding fragments
- specify CDR sequences
- provide nucleic acid molecules
- describe recombinant expression vectors
- provide binding molecules

### IV. Bispecific Antigen-Binding Molecules

- define bispecific antigen-binding molecules
- describe antigen-binding domains
- specify target antigens for first antigen-binding domain
- describe binding of first antigen-binding domain to target antigens
- specify complement components for second antigen-binding domain
- describe binding of second antigen-binding domain to complement components
- provide examples of target antigens and complement components
- describe EC50 values for bispecific antigen-binding molecules
- specify exemplary embodiments of bispecific antigen-binding molecules
- describe promotion of human C1q deposition by bispecific antigen-binding molecules
- provide additional details on bispecific antigen-binding molecules
- define bispecific antigen-binding molecules
- describe antigen-binding domains
- specify heavy chain constant regions
- describe multimerizing domains
- list bispecific antibody formats
- summarize bispecific antibodies in Table 18
- describe anti-IsdB x anti-C1q bispecific antibodies
- describe other bispecific antibodies (anti-IsdA, anti-Protein A, anti-PNAG, anti-C1fA, anti-P
- describe additional bispecific antibodies (anti-Influenza HA, anti-CD20, anti-GITR)

### Sequence Variants

- describe sequence variants of antibodies and bispecific antigen-binding molecules

### Bioequivalents

- define bioequivalents of antigen-binding molecules

### V. Therapeutic Formulation and Administration

- describe pharmaceutical compositions comprising antigen-binding molecules
- discuss routes of administration
- describe dosage forms and dosing regimens

### VI. Therapeutic Uses of the Antigen-Binding Molecules

- describe methods of using bispecific antigen-binding molecules to activate or enhance cell killing
- describe methods of reducing or depleting a population of cells that express a target antigen
- describe methods of inhibiting the growth of bacteria
- describe methods of inhibiting the growth of viruses
- describe methods of killing or inhibiting the growth of diseased cells
- describe combination therapy with additional therapeutic agents

## EXAMPLES

- provide examples of antibody preparation

### Example 1. Preparation of Anti-C1q Antibodies

- prepare anti-C1q antibodies

### Example 2. Preparation of Anti-IsdB Antibodies

- prepare anti-IsdB antibodies

### Example 3. Preparation of Anti-CD20 Antibodies

- prepare anti-CD20 antibodies

### Example 4. Preparation of Anti-Influenza HA Antibodies

- prepare anti-Influenza HA antibodies

### Example 5. Preparation of Anti-GITR Antibodies

- prepare anti-GITR antibodies

### Example 6. Preparation of Anti-Ps1 Antibodies

- prepare anti-Ps1 antibodies

### Example 7: Preparation of Anti-Protein A Antibodies

- prepare anti-Protein A antibodies

### Example 8: Preparation of Anti-IsdA Antibodies

- prepare anti-IsdA antibodies

### Example 9. Preparation of Anti-Poly-N-Acetylglucosamine (PNAG)

- produce recombinant C1q bispecific antibody REGN5536
- construct C1q binding scFv-Fc*
- purify scFv containing bispecific molecules
- obtain amino acid sequence identifiers of anti-PNAG antibody
- show sequence identifiers in Table 16
- describe expression plasmids
- provide UniProtKB/Swiss-Prot accession number
- describe bactericidal activity assay
- determine copy number of S. aureus surface antigens
- develop strategy to increase complement deposition and bacterial killing
- characterize unique binding properties of anti-IsdB x anti-C1q bsAb
- demonstrate functional consequence of bsAb-mediated enhancement of MAC deposition
- describe infection model
- present results of in vivo efficacy study
- compare efficacy of bsAb to standard of care antibiotics
- discuss implications of C1q-directed bispecific approach
- determine binding kinetics of bsAbs to various targets
- present experimental results
- describe binding of antibodies to various targets
- detail experimental procedures for binding studies
- report results of binding studies
- demonstrate ability of bispecific antibodies to bind Pseudomonas aeruginosa
- present results of anti-PNAG preparation
- demonstrate binding and CDC activity of anti-Ps1 x anti-C1q bispecific antibody
- introduce influenza infection and bispecific antibody strategy
- demonstrate binding and CDC activity of anti-Influenza HA x anti-C1q bispecific antibody
- introduce anti-CD20 x anti-C1q bispecific antibody
- describe experimental procedure for binding and CDC assays
- present results of binding and CDC assays
- introduce anti-GITR x anti-C1q bispecific antibodies
- describe experimental procedure for flow cytometric analysis and CDC assay
- present results of flow cytometric analysis and CDC assay
- summarize results of anti-GITR x anti-C1q bispecific antibodies
- introduce bispecific antibodies with IgG4 or IgG1 uber stealth Fc
- present results of C1q depletion assay

